Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 5,926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer, Laryngeal Cancer, Sinonasal Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, Skull Base Tumors, HPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions: Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Birmingham, Alabama • Denver, Colorado • St Louis, Missouri

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions: BMN 673; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Indianapolis, Indiana • Seattle, Washington • Madison, Wisconsin

Conditions: Hypercholesterolemia
Interventions: Enlicitide Decanoate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 52
States / cities: Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 48 more

Conditions: Multiple Sclerosis
Interventions: Tolebrutinib, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
Interventions: GZ17-6.02, Capecitabine; Drug
Lead sponsor: Genzada Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 1 more

Conditions: Dravet Syndrome
Interventions: EPX-100 (Clemizole Hydrochloride), Placebos; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Chronic Kidney Disease, Iron-deficiency Anemia
Interventions: IV Iron, Ferrous Sulfate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atopic Dermatitis
Interventions: PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: Tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 41
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more

Conditions: Immunologic Desensitization
Interventions: allergen extract tablet, Placebo tablet; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: COVID-19
Interventions: Saline oral/nasal rinse, 0.5% Povidone/Iodine oral/nasal rinse, 0.12% Chlorhexidine oral/nasal rinse; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Post Menopausal Osteoporosis
Interventions: Ibandronate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Female only
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 50
States / cities: Montgomery, Alabama • Chandler, Arizona • Peoria, Arizona + 46 more

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 beta estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 16 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Chronic Kidney Disease, Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 34
States / cities: Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more

Conditions: Cardiovascular Disease
Interventions: Placebo, Alpha cyclodextrin; Other · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Cachexia, Anorexia, AIDS Wasting Syndrome, HIV Wasting Syndrome
Interventions: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine, Standardized meals; Drug · Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Esophageal Motility Disorders
Interventions: Per oral endolumenal myotomy; Procedure
Lead sponsor: The Oregon Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Osteoporosis
Interventions: ibandronate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Upland, California • Boulder, Colorado • Lakewood, Colorado + 11 more

Conditions: Chronic Hepatitis B
Interventions: ACH126, 433; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 8 more

Conditions: Migraine, With or Without Aura
Interventions: Ubrogepant, Placebo-matching Ubrogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 109
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 91 more

Conditions: Advanced Chronic Liver Disease, Healthy Participants
Interventions: AZD2389, Midazolam, Caffeine, Bupropion; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Asthma, Bone Density, Low, Oral Steroid-Dependent Asthma (Disorder)
Interventions: CT Scan, DXA Scan, Steroid Intake Questionnaire; Radiation · Other
Lead sponsor: University of Iowa; Other
Eligibility: 25 Years to 45 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy

Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Endolumenal Partial Myotomy for Esophageal Motility Disorders

A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids